Real-world persistence of E/C/F/TAF versus DTG+ABC/3TC regimens for treatment of HIV in a large Spanish cohort: VACH

被引：0

作者：

Teira, R. ^{[1
]}

Romero, A. ^{[2
]}

Roca, B. ^{[3
]}

Munoz-Sanchez, M. ^{[4
]}

Sepulveda, M. ^{[5
]}

Puig, T. ^{[6
]}

Espinosa, N. ^{[7
]}

Merino, M. ^{[8
]}

Geijo, P. ^{[9
]}

Castano, M. ^{[10
]}

Estrada, V. ^{[11
]}

Ribera, E. ^{[12
]}

Domingo, P. ^{[13
]}

De la Fuente, B. ^{[14
]}

Montero, M. ^{[15
]}

Galindo, M. ^{[16
]}

Peraire, J. ^{[17
]}

Martinez, E. ^{[18
]}

Lozano, F. ^{[19
]}

Terron, A. ^{[20
]}

Garcia, J. ^{[21
]}

Deig, E. ^{[22
]}

Munoz-Sanz, A. ^{[23
]}

Gutierrez, M. ^{[13
]}

机构：

[1] Hosp Sierrallana, Torrelavega, Spain

[2] Hosp Clin, Puerto Real, Spain

[3] Hosp Gen, Castellon de La Plana, Spain

[4] Hosp Basurto, Bilbao, Spain

[5] Hosp Virgen de la Salud, Toledo, Spain

[6] Hosp Arnau Vilanova, Lleida, Spain

[7] Virgen del Rocio, Seville, Spain

[8] Hosp Infanta Elena, Huelva, Spain

[9] Hosp Virgen de la Luz, Cuenca, Spain

[10] Hosp Carlos Haya, Malaga, Spain

[11] Hosp Clin San Carlos, Madrid, Spain

[12] Hosp Valle De Hebron, Barcelona, Spain

[13] Hosp Santa Creu & Sant Pau, Barcelona, Spain

[14] Hosp Cabuenes, Gijon, Spain

[15] Hosp la Fe, Valencia, Spain

[16] Hosp Clin, Valencia, Spain

[17] Hosp Joan 23, Tarragona, Spain

[18] Hosp Albacete, Albacete, Spain

[19] Hosp Valme, Seville, Spain

[20] Hosp SAS, Jerez de la Frontera, Spain

[21] Hosp Santa Lucia, Cartagena, Spain

[22] Hosp Gen, Granollers, Spain

[23] Hosp Infanta Cristina, Badajoz, Spain

来源：

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2018年 / 21卷

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

P083

引用

页数：1

共 47 条

[31] Real world data of using Triumeq (dolutegravir/abacavir/lamivudine; DTG/ABC/3TC): final outcomes of the 3-year German TRIUMPH cohort show good virologic effectiveness and safety in clinical routine
Postel, N.
Heuchel, T.
Malfertheiner, P.
Brust, J.
Scholten, S.
Stephan, C.
Bohr, U.
Hillenbrand, H.
Lutz, T.
Glaunsinger, T.
Westermayer, B.
Lueftenegger, D.
Walli, R-K
[J]. HIV MEDICINE, 2019, 20 : 81 - 82
[32] Dual therapy with DTG+3TC or DTG+RPV versus triple therapy with B/F/TAF in virologically suppressed adults living with HIV-1: Ummunological outcomes in real-life experience
Troya, J.
Buzon, L.
Pousada, G.
Mican, R.
Galera, C.
Sanz, J.
Santos, I.
Duenas, C.
Cabello, N.
Martin, C.
Galindo, M. J.
Garcinuno, M. A.
Pedrero-Tome, R.
Ortega, D.
Matarranz, M.
[J]. HIV MEDICINE, 2023, 24 : 91 - 92
[33] Three-year outcomes for Dolutegravir (DTG) plus Lamivudine (3TC) in ARTnaive and pre-treated people living with HIV-1 (PLHIV) in Germany: Real-world data from the German URBAN cohort
Noe, S.
Scholten, S.
Wyen, C.
Sabranski, M.
Postel, N.
Degen, O.
Beer, D.
Ummard-Berger, K.
Westermayer, B.
Dymek, K. M.
Scherzer, J.
[J]. HIV MEDICINE, 2023, 24 : 137 - 139
[34] COST-EFFECTIVENESS ANALYSIS OF DOLUTEGRAVIR/ LAMIVUDINE (DTG/3TC) VERSUS ELVITEGRAVIR/ COBICISTAT/TENOFOVIR ALAFENAMIDE/EMTRICITABINE (EVG/C/TAF/FTC) FOR HIV-1 INFECTION MANAGEMENT IN TREATMENT-EXPERIENCED PATIENTS IN CHINA
Fan, L.
Tang, Z.
Jacob, I
Anderson, S. J.
Kabra, M.
Turner, M.
Tewary, A.
Harrison, C.
[J]. VALUE IN HEALTH, 2023, 26 (06) : S82 - S82
[35] Effectiveness, persistence and safety of E/C/F/TAF, F/TAF+3rd agent or R/F/TAF use in treatment-naive HIV-1 infected patients: 12-month results from the German TAFNES cohort study
Heuchel, T.
Hillenbrand, H.
Jessen, H.
Pauli, R.
Postel, N.
Haubrich, R.
Heinzkill, M.
Goerner, K.
Stellbrink, H.
[J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
[36] 24-month evaluation of the German TAFNES cohort - Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), F/TAF+3rd agent or rilpivirine/F/TAF (R/F/TAF) in treatment-experienced HIV-1 infected patients
Knechten, H.
Schneeweiss, S.
Schuebel, N.
Hillenbrand, H.
Kuemmerle, T.
Schreiber, S.
Goerner, K.
Heinzkill, M.
Haubrich, R.
Stellbrink, H-J
[J]. HIV MEDICINE, 2019, 20 : 60 - 61
[37] Comparison of the efficacy, safety and durability of a switch to co-formulated RPV/TDF-TAF/FTC or DTG/ABC/3TC in virologically-suppressed HIV-1-infected patients in a single Italian centre: a cohort data analysis
Lagi, Filippo
Botta, Annarita
Kiros, Seble Tekle
Meli, Massimo
Borchi, Beatrice
Cavallo, Annalisa
Pozzi, Marco
Bartoloni, Alessandro
Sterrantino, Gaetana
[J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2022, 59 (01)
[38] The effectiveness of E/C/F/TAF in treatment-naive (TN) or treatment-experienced (TE) adult HIV-infected patients in a real-world setting, results from southern Turkey
Inan, D.
Ulu, A. Candevir
Yildirim, F. Sarigul
Ersoz, G.
Komur, S.
User, U.
Kandemir, O.
Kuscu, F.
Cuvalci, N. Oztoprak
Inal, A. S.
Celen, M. K.
Saba, R.
Kurtaran, B.
Tasova, Y.
[J]. HIV MEDICINE, 2019, 20 : 82 - 83
[39] Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), F/TAF+3rd agent or rilpivirine/F/TAF (R/F/TAF) in treatment-naive HIV-1 infected patients-24-month results from the German TAFNES cohort study
Pauli, R.
Jessen, H.
Postel, N.
Heuchel, T.
Rieke, A.
Hillenbrand, H.
Kuemmerle, T.
Schreiber, S.
Goerner, K.
Heinzkill, M.
Haubrich, R.
Stellbrink, H-J
[J]. HIV MEDICINE, 2019, 20 : 54 - 55
[40] Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), rilpivirine/F/TAF (R/F/TAF) or F/TAF + another 3rd agent in HIV-1+patients over 24 months - Results from the German TAFNES cohort study
Stellbrink, H.
Scholten, S.
Hillenbrand, H.
Knechten, H.
Jessen, H.
Schreiber, S.
Goerner, K.
Haubrich, R.
Heinzkill, M.
[J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 54 - 55

← 1 2 3 4 5 →